Looking To The Future of FRα-Directed Antibody-Drug Conjugates
- Emerging data around sofetabart mipitecan (LY4170156) are drawing attention because they challenge several assumptions established during earlier FRα development. In early clinical development, benefit was reported across a spectrum of expression levels, including cohorts that would traditionally be excluded from FRα-targeted therapy.
- In efficacy-evaluable patients (n = 104), LY4170156 demonstrated an overall response rate of 50% and a disease control rate of 78%.
- Responses included 48 partial responses and 4 complete responses, indicating meaningful depth of response in a heavily pretreated population.
- Among responding patients, 73% remained on active treatment at the time of data cutoff, suggesting durability of benefit for a substantial subset.
After nearly three years of real-world experience with folate receptor alpha (FRα)-directed antibody-drug conjugates (ADCs) in platinum-resistant ovarian cancer, most notably, mirvetuximab soravtansine (Elahere), clinicians are no longer asking whether the target matters, but how much broader that target can be. Emerging data around sofetabart mipitecan (LY4170156) are drawing attention precisely because they challenge several assumptions established during earlier FRα development.
Gynecologic oncologists navigating this space note that the most practice-changing feature is not incremental response rates, but patient eligibility. Unlike earlier FRα-directed ADCs that required high FRα expression by immunohistochemistry, sofetabart mipitecan appears to demonstrate activity in patients with low or even absent FRα expression.
“They had patients with low expression, less than 50%. They had patients with even no expression where they did see benefit. Additionally, this was a phase I study which had over a hundred patients, and more importantly, the had four complete responses,” Dr. Premal Thaker, a gynecologic oncologist/surgeon at Siteman Cancer Center in St. Louis, tells SurvivorNet Connect.
Promising Early Data
In early clinical development, benefit was reported across a spectrum of expression levels, including cohorts that would traditionally be excluded from FRα-targeted therapy. If borne out in phase III analyses, this alone meaningfully expands the treatable population. The current phase III trial exists (FRAmework-01; NCT07213804), but phase III efficacy results are not public yet. Expected completion is around August 2031 (per registry).
Another differentiator is depth of response. Phase I experience included complete responses in heavily pretreated patients, an uncommon finding at that stage of development, where partial responses or disease stabilization are typically considered success signals. While cross-trial comparisons should be avoided, this qualitative shift has generated cautious optimism that payload selection, linker stability, or intracellular delivery may be mechanistically distinct from first-generation FRα ADCs.
In terms of current available data/numbers, among efficacy-evaluable patients (n = 104), sofetabart mipitecan demonstrated an overall response rate of 50% (52 patients), including 4 complete responses and 48 partial responses. The disease control rate was 78% (81 patients). At the time of reporting, 73% of responders (n = 38) remained on treatment, while 14 patients had discontinued therapy, including 6 due to disease progression.
Toxicity Profile & Operational Impact
From a tolerability standpoint, what stands out is not the absence of adverse events, but their nature. Thus far, reported toxicities have been dominated by nausea and fatigue, without the ocular toxicity that has required prophylactic ophthalmologic monitoring and additional clinic infrastructure with earlier agents.
“They’re very manageable side effects, not needing the extra appointments,” Dr. Thaker explains. “It will be much easier for adoption as we talk about making it more widespread. This would make it an easier compound to administer.”
For clinicians, this has real implications for adoption, especially in community settings where access to frequent eye exams can be a barrier.
Key Treatment Decision Points
While it is not FDA approved, several questions will likely shape prescribing decisions:
- FRα testing: Will broad efficacy reduce reliance on strict expression cutoffs, or will subgroups still derive differential benefit?
- Line of therapy: Where does this agent fit relative to existing ADCs, PARP inhibitors, and clinical trials?
- Patient fitness: Fatigue and gastrointestinal effects may still limit use in frail or heavily comorbid patients.
- Combination potential: Whether synergy with chemotherapy or immunotherapy improves durability remains an open question.
Beyond FRα expression, there are no validated biomarkers yet to predict response. Exploratory analyses around tumor heterogeneity, drug efflux mechanisms, or immune microenvironment may become relevant but are not ready for clinical decision-making. Fertility considerations, drug–drug interactions, and cumulative toxicity in long-surviving patients will also require longer follow-up.
Assuming confirmatory phase III efficacy and manageable safety, a regulatory pathway is realistic, though dependent on final endpoints and comparator arms. For now, sofetabart mipitecan represents not just another FRα agent, but a potential reframing of how broadly this target can be leveraged in ovarian cancer.
